Therapeutic Effect of Nizatidine for Active Duodenal Ulcers

Nizatidine：一種新的組織胺受體阻斷劑對活動性十二指腸潰瘍之療效評估

謝忠平(Jong-Pyng Hsieh) ； 趙有誠(You-Chen Chao) ； 葉淳(Chun Yeh) ； 何愛生(Ai-Sheng Ho) ； 張維國(Wei-Kao Chang) ； 曹為霖(Wei-Lin Tsao) ； 唐鴻舜(Hung-Shang Tang) ； 許重得(Chung-Te Hsu)

《Journal of Medical Sciences》 13卷6期 (1993/06) Pp. 405-410

摘要

The aims of this study are to assess the efficacy of nizatidine and investigate the influence of nizatidine on gut hormone (gastrin and pepsinogen I) before and after treatment in the active duodenal ulcer patients. Fifty patients of both sexes (male: female 42: 8), age more than 18 years, had a mean age of 34.3 years, ranging from 19 to 77 years, with active duodenal ulcers documented by UGI panendoscopy, who had no history of chronic, systemic disease or long-term use of extrapeptic drugs were selected from the Gastrointestinal OPD of Tri-Service General Hospital and included in this open-Iabel study. Daily dose of nizatidine 300 mg (150 mg po bid) were given for 4 to 8 weeks. The clinical symptomatology, ulcer status, serum levels of gastrin and pepsinogen I were evaluated before and after treatment. The final results demonstrated that the symptoms of day and night epigastric pain after 2, 4, and 8 weeks of treatment were significantly improved (p ＜ 0.001 ) compared with those before treatment. The complete endoscopic healing rates after 4, and 8 weeks of treatment were 72%, and 87%. Statistically, there were no significant differences of serum concentrations of gastrin and pepsinogen I before and after treatment. We concluded that nizatidine could act as an effective drug of active duodenal ulcers and did not affect serum levels of gut hormone (gastrin and pepsinogen I) before and after treatment.

關鍵字

十二指腸潰瘍 ； 胃泌素 ； 胃蛋白酶原I

並列摘要

The aims of this study are to assess the efficacy of nizatidine and investigate the influence of nizatidine on gut hormone (gastrin and pepsinogen I) before and after treatment in the active duodenal ulcer patients. Fifty patients of both sexes (male: female 42: 8), age more than 18 years, had a mean age of 34.3 years, ranging from 19 to 77 years, with active duodenal ulcers documented by UGI panendoscopy, who had no history of chronic, systemic disease or long-term use of extrapeptic drugs were selected from the Gastrointestinal OPD of Tri-Service General Hospital and included in this open-Iabel study. Daily dose of nizatidine 300 mg (150 mg po bid) were given for 4 to 8 weeks. The clinical symptomatology, ulcer status, serum levels of gastrin and pepsinogen I were evaluated before and after treatment. The final results demonstrated that the symptoms of day and night epigastric pain after 2, 4, and 8 weeks of treatment were significantly improved (p ＜ 0.001 ) compared with those before treatment. The complete endoscopic healing rates after 4, and 8 weeks of treatment were 72%, and 87%. Statistically, there were no significant differences of serum concentrations of gastrin and pepsinogen I before and after treatment. We concluded that nizatidine could act as an effective drug of active duodenal ulcers and did not affect serum levels of gut hormone (gastrin and pepsinogen I) before and after treatment.

並列關鍵字

Duodenal ulcer ； Gastrin ； Pepsinogen I